Announcing our Biosimilars Council “Member Spotlight” Series
This summer, as part of our commitment to broad stakeholder education about the promise of biosimilars, the Biosimilars Council will launch the first in a series of “member spotlights” – in-depth content featuring experts from our member companies sharing their unique experience and perspective on timely issues impacting the emerging biosimilars marketplace.
We are excited to share with the broader stakeholder community the expertise and resources that each of our member companies brings to these important discussions. We’ll tackle important topics like regulatory policy, scientific development and patient access. Each spotlight will feature Q&A, blogs, social media content and graphics on a timely topic of relevance to the emerging biosimilar marketplace, to help our stakeholders gain a deeper understanding of the promise of biosimilars for their communities. We’re thrilled to kick our Spotlight Series off this month with Dr. Hillel Cohen, Executive Director of Scientific Affairs for Sandoz.
Dr. Cohen currently leads Scientific Affairs efforts for Sandoz in the Americas where he helps explain the science-based Sandoz and Novartis biosimilar policy positions to the healthcare community, the public, and health authorities.
Active in field of biosimilars since 2002, when discussions about them were initiated in the U.S., Dr. Cohen is an expert in regulatory science policy and biologic product development. With over 25 years of experience, Dr. Cohen has been a regular contributor and thought leader in biosimilars, leveraging his background to advance biosimilars for the benefit of all patients.
Over the coming months, Dr. Cohen will be featured on our various Biosimilars Council channels discussing current biosimilars policies in the U.S., specifically relating to interchangeability and the FDA’s current proposed update to their policy on biosimilar naming– both key issues pending before the FDA which have the potential to significantly impact the uptake of biosimilars and patient and provider confidence in these products.
About the Biosimilars Council
The Biosimilars Council, a division of the Association for Accessible Medicines (AAM), works to ensure a positive environment for patient access to biosimilar medicines. The Biosimilars Council is a leading source for information about the safety and efficacy of more affordable alternatives to costly brand biologic medicines. Areas of focus include public and health expert education, strategic partnerships, government affairs, legal affairs and regulatory policy. More information is available on our about page.
AAM is driven by the belief that access to safe, quality, effective medicine has a tremendous impact on a person’s life and the world around them. Generic and biosimilar medicines improve people’s lives, improving society and the economy in turn. AAM represents the manufacturers and distributors of finished generic pharmaceuticals and biosimilars, manufacturers and distributors of bulk pharmaceutical chemicals, and suppliers of other goods and services to the generic industry. Generic pharmaceuticals are 90 percent of prescriptions dispensed in the U.S. but only 23 percent of total drug spending. Additional information is available at www.accessiblemeds.org.